Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).
Victor Gonzalez, MD
Advertisement
Articles by Victor Gonzalez, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
5